Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. uri icon

Overview

authors

publication date

  • May 16, 2022

Research

keywords

  • COVID-19 Drug Treatment
  • Hematologic Neoplasms

Identity

PubMed Central ID

  • PMC9108069

Scopus Document Identifier

  • 85132188475

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2022.05.007

PubMed ID

  • 35598602

Additional Document Info

volume

  • 40

issue

  • 6